People · Operator
Named in public records as an officer, director or promoter · active 2013–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Amunix Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $203.9M | $3.9B | 2020 |
| Aravive, Inc. | — | Biotechnology | Series C | $156.1M | $702.9M | 2013 |
Volker Schellenberger at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Volker Schellenberger on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Hirsch | 1 | 16 |
| James Topper | 1 | 12 |
| Kevin Johnson | 1 | 12 |
| Srinivas Akkaraju | 1 | 10 |
| Anthony Sun | 1 | 8 |
| MICHAEL DYBBS | 1 | 5 |
| Otello Stampacchia | 1 | 4 |
| Shahzad Malik | 1 | 4 |
| Michael W. Rogers | 1 | 4 |
| JEFFREY CLELAND | 1 | 4 |
| Francesco De Rubertis | 1 | 4 |
| Jay Shepard | 1 | 3 |
| Richard Heyman | 1 | 2 |
| Joshua Brumm | 1 | 2 |
| Trisha Millican | 1 | 2 |
| Fredric N. Eshelman | 1 | 2 |
| Gail McIntyre | 1 | 2 |
| Angie You | 1 | 2 |
| Edmon Jennings | 1 | 1 |
| Rudy N. Howard | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.